RxDoctor Payments Data

Imelda Miranda, MD

Internal Medicine · Upper Marlboro, MDNPI 1578510681

Payments from drug & device makers

$6,855in general payments, 2019–2025

Across 362 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$701
  • Novo Nordisk$567
  • Merck$324
  • Pfizer$293
  • Sanofi-aventis U.S. LLC$283
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$6,76099%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,855 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$115,486
Medicare patients
388
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate65$74,099
JardianceEmpagliflozin37$56,920
MounjaroTirzepatide15$38,576
FarxigaDapagliflozin Propanediol25$37,292
TrulicityDulaglutide20$34,580
EliquisApixaban19$29,158
TradjentaLinagliptin21$28,536
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$21,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$19,558
JanumetSitagliptin Phos/Metformin Hcl18$19,059
Atorvastatin Calcium363$5,198
Diclofenac Sodium11$4,024
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid32$3,996
Rosuvastatin Calcium164$3,544
Nano 2nd Gen Pen NeedlePen Needle, Diabetic27$2,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$324$93,15883 claims
Boehringer IngelheimJardiance, Tradjenta$235$85,45658 claims
Lilly USA, LLCMounjaro, Trulicity$701$73,15635 claims
AstraZenecaFarxiga$1,559$37,29225 claims
PfizerEliquis$293$29,15819 claims
GSKTrelegy Ellipta$117$19,55813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Upper Marlboro

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →